SCHEMBL30714724

SCHEMBL30714724

Cn1nc2ccc(OCc3ccccc3F)cc2c1C(=O)NC1(C(N)=O)CCOCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 2/20 0.45
MMP1 P03956 1/20 0.45
PARP15 Q460N3 3/20 0.40
PARP10 Q53GL7 3/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KCNH2 Q12809 2/20 0.39
MAOB P27338 4/20 0.38
PARP14 Q460N5 1/20 0.38
MMP3 P08254 2/20 0.38
MMP7 P09237 2/20 0.38
ADAMTS4 O75173 1/20 0.38
ADAM17 P78536 1/20 0.38
ADAMTS1 Q9UHI8 1/20 0.38
ADAMTS5 Q9UNA0 1/20 0.38
SCN3A Q9NY46 5/20 0.37
SCN9A Q15858 1/20 0.37
MMP2 P08253 1/20 0.37
MMP12 P39900 1/20 0.37
RARA P10276 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714663 0.95 MMP13 (0.42) MMP13MMP1PARP15PARP10NPC1
SCHEMBL30714736 0.88 ADAM17 (0.43) MMP13MMP1PARP15PARP10NPC1
SCHEMBL30714648 0.87 ADAM17 (0.35) MMP13MMP1KCNH2MMP3MMP7
SCHEMBL30714638 0.86 P2RY12 (0.39) PARP10KCNH2
SCHEMBL31539884 0.84 MAOB (0.39) MMP13MMP1PARP15PARP10NPC1
SCHEMBL30714628 0.83 PARP15 (0.40) MMP13MMP1PARP15PARP10NPC1
SCHEMBL30714574 0.83 CD38 (0.33) MMP13MMP1MMP3MMP7ADAMTS4
SCHEMBL31539870 0.82 PARP10 (0.38) PARP15PARP10NPC1RAB9AKCNH2
SCHEMBL30714753 0.82 PARP15 (0.39) MMP13MMP1PARP15PARP10NPC1
SCHEMBL30714728 0.82 CNR2 (0.34) MMP13MMP1NPC1RAB9AMMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 MMP13 1106/4885MMP1 2512/4885PARP15 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.